Method of inhibiting HIV-1 replication by administering modified GP41 C34 peptide derivatives with enhanced pharmacological properties
US8470527B2 · kind B2 · utility
0Cited by
8References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 25, 2009 |
| Grant date | Jun 25, 2013 |
| Priority date | — |
| Expiry date | Dec 27, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16122
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The claimed invention is directed toward modified HIV-1 gp41 C-terminal heptad repeat fusion inhibitors. In particular, peptide derivatives of C-34 were prepared (e.g., FB006M) and modified with 3-maleimidoproionic acid (MPA), which allows rapid and irreversible conjugation to serum albumin at a 1:1 molar ratio. These polypeptides have an extended half-life in vivo and display potent antiviral activity against HIV-1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.